OJC 2023 Practice-Changing Papers: Part 2
The Oncology Network is delighted to share the second part of a new episode of…
Browsing: Featured
OJC 2023 Practice-Changing Papers: Part 1
The Oncology Network is delighted to share the first part of a new episode of The…
Fungus-fighting protein could help overcome severe autoimmune disease and cancer
A protein in the immune system programmed to protect the body from fungal infections is…
ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia
Non-Hispanic Black patients with acute myeloid leukaemia (AML) are living longer, now that new therapies are available,…
New health mapping study pinpoints cancer risk factors at local level
A new QUT-led study that maps health statistics in Australia highlights the disparities in small…
Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for the treatment of relapsed or refractory mantle cell lymphoma (r/r MCL)
This content is password-protected. To view it, please enter the password below. Password:
Chefs, comedians and celebrities show their cheeky side for a new ‘rude food’ fundraising cookbook
The new ‘Rude Food’ cookbook from ‘below the belt’ cancer research organisation, ANZUP, showcases some…
Lesbian, gay, and bisexual survivors of adolescent and young adult cancers often have chronic health conditions
Lesbian, gay, and bisexual (LGB) adolescents and young adult cancer survivors in the United States…
Mathematics supporting fresh theoretical approach in oncology
Mathematical approaches are gaining traction in modern oncology as they provide fresh knowledge about the evolution of cancer and new opportunities…
SABCS 2023: Tucatinib plus trastuzumab emtansine may benefit patients with advanced or metastatic HER2-positive breast cancer
A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free…